Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

By A. Howell, Jack Cuzick, M. Baum, A. Buzdar, Mitchell Dowsett, J. Forbes, G. Hoctin-Boes, J. Houghton, G. Locker, J. Tobias. The Lancet, 2005

2,354 citations recorded by the source corpus.

Subfields: Cancer Research, Genetics, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/21f0d611f8d7e92d6dbf5ac243806565f3024f11

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. W. Wood
2. J. Glick
3. B. Thürlimann
4. H. Senn
5. Panel Members

Citations in the corpus

• Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. (2007, background): “Clearly the availability of third generation aromatase inhibitors (AIs) [24, 84–88] has added substantially to the available treatment choice after a quarter century of successful use of tamoxifen.”
• Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. (2005, background): “Endocrine therapies Initial adjuvant endocrine therapy with the aromatase inhibitors anastrozole or letrozole was tested in large trials against tamoxifen and found to significantly reduce relapse among postmenopausal women with endocrine responsive disease [66, 67].”